

## **Max India Limited**

## **Investor Presentation**

This presentation is a compilation of unaudited financial and other information. This may also contain statements that are forward looking. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from our expectations and assumptions. We do not undertake any responsibility to update any forward looking statements nor should this be constituted as a guidance of future performance.



## Max India – An Introduction

Max India Limited is a multi-business corporate, driven by the spirit of Enterprise, focused on Knowledge, People and Service oriented businesses of Life Insurance, Healthcare and Clinical Research. Max's other businesses are Speciality Plastic Products for the packaging industry and Healthcare Staffing.



BSE Scrip Code: 500271, NSE Ticker: Max, Bloomberg: Max IN

Create service excellence in all businesses



## Max India – Key Highlights

- Promoted by Mr. Analjit Singh a prominent Indian industrialist, in 1988
- Amongst one of the leading conglomerates in India
  - Life Insurance 74:26 JV with New York Life... 5% Market Share amongst Private Players
  - Healthcare 70% Owned... 8 Healthcare Facilities with 770 Beds.
  - Clinical Research 100% Owned... over 200 Active Sites
  - Speciality Packaging Division... Capacity of 29,000 TPA; 100% Utilization
  - Health Staffing 100% Owned... 500 Nurses in the Program
- 2.5 Million Customers... 12,000 Employees... 38,500 Agents... 1,250 Doctors...
- Track record of successful international Business Partnerships over last 20 years






## **Consolidated Performance Snapshot**

US\$ Mn

CONSOLIDATED FINANCIAL HIGHLIGHTS					
Particulars	2007-08	2006-07	Growth %		
Operating Revenue	811.0	454.8	78%		
Investment and Other Income	91.6	43.6	110%		
Total Revenue	902.6	498.4	81%		
EBITDA	17.6	5.1	245%		
EBIT	1.1	(6.4)			
Net Income Before Tax	(10.8)	(13.9)			
Shareholders' Funds	385.9	150.7	156%		
Preference Shares**	62.5	0.0			
Borrowings***	94.4	96.1	-2%		
Fixed Assets (Net Block)	179.6	157.1	14%		
Treasury Corpus	315.3	71.3	342%		
Life Insurance Investments	893.7	458.9	95%		
Net Current Assets	64.6	29.1	122%		



<sup>\*</sup> Excludes one-time revenue of US\$ 106.9 Mn on sale of stake in Hutchison Essar Ltd.




## Max India – Shareholding

Number of Outstanding Shares 222,022,720

Market Capitalization

Approx. US\$ 1 Billion

Shareholding Pattern – March 31, 2008





## Max India – Management Team

Name	Profile Profil
Mr. Analjit Singh	Mr. Analjit Singh, Chairman & Managing Director, Max India has been the driving force behind Max Group's sustained growth and success since the early 80's. Mr. Singh a prominent industrialist is an alumnus of Doon School; University of Delhi, and the Graduate School of Management, Boston University







## **Max New York Life Insurance**





## India's Life Insurance Industry is Witnessing Rapid Growth





#### Strong Growth driven by...

- Low Penetration Level
- Increasing Per Capita Income
- Strong GDP Growth
- Absence of Social Security Cover
- Increasing Awareness
- Better Distribution
- Availability of Multiple Products
- Increased Life Expectancy





## Max New York Life Insurance [ MNYL ]

- Joint Venture between Max India and New York Life International [ NYL ]
- NYL, one of Fortune 100 companies, is the oldest mutual life insurance company in the US with around \$250 billion in assets under management
- Max India and NYL jointly drive the growth strategy
- Max provides Indian industry perspective and manages the regulatory environment
- Peak equity commitment of over US\$ 650 Mn US\$ 258 Mn already infused









## MNYL road map to becoming India's most admired Life Insurance Company

#### **Key Public Messages**

- A trusted life insurance specialist
- Customer centric
- Financially responsible and strong

Financial Strength & Security

A great place to work

**Key Differentiators** 

An admired member of the community

- **GOALS**
- Quality of agents
- Flexible Products
- Service Excellence
- Fair Terms of Business

#### **KEY**

**OBJECTIVES** 

#### **STRATEGIES**

#### **INITIATIVES**

#### **VALUES & BELIEFS**

- Excellence
  - Caring Honesty Integrity
- Knowledge
- Teamwork

#### **OPERATING PRINCIPLES**

levels

- Customer comes first
- International quality standards
- Do it right the first time
- Fact based decisions
- Bias for result oriented action
- Financial strength & discipline
- Direct and open communication Respect Max & NYLI values & parentage
- Fun at work

#### Ratios

#### Become the most admired Life Insurance Company in India VISION

- Part of top quartile new Life Insurance Companies
- National Player
- Brand of FIRST choice **MISSION** 
  - **Employer of Choice**
  - **Principal of Choice for Agents**

#### 4 Billion \$ in Premiums in 10th year IRR-20% plus; Dominate MDRT in

India; Profitable by 2010

- WHAT Comprehensive suite of products, competitive pricing, extensive distribution, persistency, customer service excellence,
- profitable portfolios
- HOW Talented People, Professional & Productive Agents,
- Performance Metrics, Leverage Technology, Teamwork, Customer
- Centric, Innovative Distribution and Marketing

#### **METRICS & STANDARDS**

Input

What-When-Who-How-Cost linkage plans at Departmental and Individual

- Output
- External
- Internal
- Absolute

#### PERFORMANCE MGMT **PROCESS**

- GMPR Ratings
- TEC/TTR Templates
- Primary, Shared and Contributory
- Balanced scorecard
- Core. Functional and **Leadership Competencies**



## MNYL – Management Team

Name	Profile






## **MNYL** – Key Differentiators

- One of India's leading private providers of life insurance, a well recognized brand name and strong parentage
- Full suite of products with a focus on protection
- Long tenor products (Average Tenor 26 Years), Young Customer Base (Average Age 33 Years)
- Highly productive agency led sales force with best –in-class training infrastructure
- Strong and extensive distribution channels
  - Over 38,500 exclusive sales agents in 266 offices across 170 locations
  - 18 bancassurance relationships
  - 14 corporate agents
  - Over 800 people strong direct sales team
- Strong customer trust and credibility
- Superior and innovative customer support network





## **Protection Oriented, Longer Tenor Life Insurance**







## **Established Ourselves amongst** the Leading Agency Sales Force

Adjusted Single premium

		·		justed onigie premium
	New Business Apr – March 08 (Agency) (US\$ Mn)	Agents	Premium per Agent * (\$)	Cases per Agent *
Allianz (II)	1085	290,000	358	0.83
OICICI PRUDENTIAL	1065	291,000	338	0.54
RELIANCE Anil Dhirubhal Ambani Group Life Insurance	434	185,000	257	0.60
SBI Life	365	40,000	931	1.36
HDFC	285	150,000	207	0.35
Birla Sun Life	248	100,000	264	0.62
Your Partner for Life	233	36,896	621	1.46
ING Vysya	135	53,000	258	0.65
kotak Life Insurance	129	40,000	332	0.48
AIG	92	40,000	226	0.60
MetLife &	86	35,000	257	0.37
AVIVA	86	34,000	228	0.44
* 1:- 1	et now business promium (Ago			

<sup>\*</sup> In terms of highest new business premium (Agency)






# Market Position – FY 2007-08 Insurance Sales (US \$ Mn)


Company	Individual New Business Individual Policies ('000)			
Company	Premium (FY 2007-08)	(FY 2007-08)		
ICICI Prudential	1,671	2,913		
Bajaj Allianz	1,411	3,744		
SBI Life	663	926		
<b>HDFC Standard Life</b>	554	949		
Reliance Life	468	1,074		
Birla Sunlife	428	688		
Max New York Life	327 7	873 6		
Aviva	246	390		
Tata AIG	677	497		
All Others	198	1,205		
Total Private Life Insurers	6,643	13,259		
MS of Private Players (%)	50	26		





## **MNYL** – Key Highlights






# Agency Strength 200,000 Agents by 2011 25,048 15,285 9,017

2006-07

2007-08

2005-06



2004-05





## **MNYL** – Key Highlights

Voy Pyrainaga Dviyaya	Heit	Quarter	Ended	Q-o-Q	Year E	nded	Y-o-Y
Key Business Drivers	Unit	Mar-08	Mar-07	Growth	Mar-08	Mar-07	Growth
a) Sales Value (Annualized first year premium)	US\$ Mn	143	79	81%	419	243	73%
b) Average case size	US\$	519	577	-10%	549	547	1%
c) Case rate per agent per month	No.	1.50	1.58	-5%	1.46	1.63	-10%
d) Number of agents	No.	-	-		36,896	25,048	47%
e) Net agents added	No.	6,992	4,061		11,848	9,763	
f) Conservation ratio*	%	86%	74%		83%	78%	
g) Gross written premium income	US\$ Mn						
First year premium		120	64	87%	332	188	77%
Renewal premium		98	50	95%	279	147	90%
Single premium		20	14	43%	68	40	69%
Total		238	128	86%	679	375	81%
h) Paid up Capital	US\$ Mn				258	183	41%
i) Individual Policies in force	No.				1,750,725	1,098,230	59%
j) Sum insured in force	US\$ Bn				17	11	56%

<sup>\*</sup> Conservation Ratio = Renewal Premium for the current period / (First Year+Renewal Premium for the previous period) US\$ 1 = INR 40





## **MNYL** – Growth Strategy

- Continue to focus on protection oriented, long tenor products and enhance product offerings
- Grow from 38,500 agents to 200,000 agents while optimizing on costs by agency segmentation
- Expand Footprint Pan India presence with 600 offices covering over 450 locations
- Expand Other Distribution Channels
  - Seek a large bancassurance partner with pan India presence
  - Strengthen alternate distribution channel
  - Scale up direct sales team
- Product offerings across the spectrum of saving needs Life, Health, Retirement &
   Child benefit
- Tap bottom of the pyramid by launching low value high volume products




## **Max Healthcare**

www.maxhealthcare.in






## **Indian Healthcare**



#### **Key Drivers**

- Shift to Lifestyle-Related diseases
- Growing Middle class
- Changing Spending Patterns
- Infrastructure Needs
- Health Insurance
- Medical Value Travel

#### Healthcare Industry 2012 - US\$ 78.6 Bn



#### Healthcare Industry 2012 – US\$ 78.6 billion

- Revenue generated by private hospitals currently estimated at US\$ 15.5 billion, likely to increase to US\$ 35.9 billion by 2012
- Industry expected to add 1 million beds by 2012
   private sector to contribute 89% of these beds at an investment of US\$ 70 billion





## Max Healthcare Model

- Heart and Vascular Institute
- Super Speciality Hospital

**TERTIAR** 

- Heart and Vascular
- Neurosciences
- Joint Replacement and Orthopaedics
- Obstetrics and Gynaecology
- Paediatrics

- Hospitals 4
- Speciality Centres 2

#### **SECONDARY**

- Surgery and inpatient facilities
- High-end Diagnostics:MRI, CT
- Doctor Consultation
- Eye and Dental Care

• Clinics / Implants - 9

#### **PRIMARY**

- Specialist doctor consult and full time nurse.
- Basic diagnostics likePathology Collection

**Enable retention of patient traffic** 

Enable 'start-to-finish' comprehensive, seamless care: Consult and Diagnostics, Diagnostic tests, surgeries, post-surgical care





## **Max Healthcare Credo**

**Passion** 

Build Trust

**Vision** 

Deliver world-class healthcare with a service focus, by creating an institution committed to the highest standards of medical & service excellence, patient care, scientific knowledge & medical education

#### **Mission**

Create unparalleled standards of medical & service excellence

- Care provider of FIRST CHOICE
- Principal choice for physicians
- Ethical practices
- Create national centre of excellence for select super-specialities
- Build towards international 'reach' by creating patient confidence through professional skills, research and technology



## **Max Healthcare – Management Team**

Name	Profile



## **Max Healthcare – Key Physicians**

Name	Profile Profil




## **Key Differentiators**

- Comprehensive, integrated and world-class healthcare services with state-of-the-art infrastructure and facilities
- Proven reputation in Medical Quality and Service Excellence.
- Seamless delivery of services at every level of care
- Established brand name throughout India with a network of specialist doctors
- Network of hospitals with a geographical spread that covers the entire National Capital Region
- Leadership in Key Super-Specialties in Tertiary Care
  - Centres of Excellence in Cardiac, Orthopeadics and Joint Replacement, Neuro Sciences, Pediatrics,
     Obstetrics & Gynaecology and Aesthetic & Reconstructive Surgery
- High Quality Nursing and Paramedic Care supported by Nursing and Paramedic College
- Extensive emphasis on Medical Training and Education.
- Memorable Brand Experience
  - 'Star' & Quality Physicians
  - Infrastructure and Equipment
  - No Surprises Cost of Care, Pricing, Medication
  - Signage
  - Look Feel Smell Touch






## **Key Differentiators**






## **Accreditations and Awards**





#### First in North India to get NABH on Feb. 6th, 2007





## **Express Healthcare Excellence Awards (2007 – 08)**

"Innovative Marketing Practices"



"Best Managed Healthcare Program (Health Insurance/TPA)"





## Max Healthcare - Key Highlights

Fact	t Sh	eet

#### **Shareholding pattern**

**Healthcare Facilities** 8

Physicians 1,250\*

Other Support Staff 2,700

Patient Base Over 560,000

Patient Transactions Over 135,000 pm

4

Beds 770


ICU Beds 196

OTs 20

Cathlabs 3

MRIs 4


CTs







## Max Healthcare – Key Highlights







## Tertiary Care Facility, Saket [South Delhi]



ISO 9001:2000 Certified NABH Accredited

## MAX HEART & VASCULAR INSTITUTE (December 2004)

- 200 patient beds (including 56 critical care beds)
- 3 OTs, 2 Cardiac Catheterization Labs
- Post Surgery Critical Care Unit
- High Dependency Unit
- Apex and Advanced Coronary Care
- Exclusive well equipped 'Observation Bay' and 'Post Cath. Recovery'
- Nuclear Diagnostic Services with Variable Angle Dual Head Gamma Camera
- Centralized Emergency Command with Advanced Cardiac Life Support Ambulances and Air Evacuation Service
- High-end General Surgery





## Tertiary Care Facility, Saket [South Delhi]



**NABH Accredited** 

## MAX SUPER SPECIALITY HOSPITAL (May 2006)

- 188 beds (including 63 critical care beds)
- 7 OTs, 20 Consult Chambers
- Tower Specialties Orthopaedics, Neuro Sciences, Obstetrics & Gynaecology and Paediatrics
- Brain Suite (first in Asia) and Intra Operative MRI
- DSA Lab (for Neuro Sciences)
- Emergency Services
- High end Radiology facilities with 64 slice Cardiac
   CT





## Secondary Care Facility [ Delhi ]



PITAMPURA (February 2002) (North Delhi)

- 90 inpatient beds
- 2 OTs
- Lithotripsy
- Mother and Child care
- Non-Invasive Cardiology
- Plastic and Reconstructive surgery
- Physiotherapy
- Full range diagnostics
- PHP, OPD and Dentistry



PATPARGANJ (May 2005) (East Delhi)

- 147 inpatient beds
- 3 OTs
- Mother and Child care
- Orthopaedics
- General Surgery
- Critical care including Dialysis
- Non-invasive Cardiology (incl. Cardiac Catheterization Lab)
- ENT, Ophthalmology
- Other allied specialties





## Secondary Care Facility [Suburb of Delhi]



GURGAON (July 2007) (Suburb)

- 108 Inpatient beds
- 3 OTs
- Ophthalmology (Anterior and Posterior)
- Woman and Child (including Infertility)
- Medical & Surgical Intensive Care
- Orthopaedics
- Nephrology and Urology
- Aesthetic and Reconstructive Surgeries
- General and Minimally Invasive surgeries
- PHP and OPD



NOIDA (August 2002) (Suburb)

- 39 inpatient beds
- 2 OTs
- Mother and Child care
- Non-Invasive Cardiology
- Laparoscopic Surgery
- Orthopaedics
- ENT, Ophthalmology
- Urology and Nephrology
- Full range diagnostics
- PHP, OPD and Dentistry





## **Speciality Centres – Panchsheel [South Delhi]**



## **OPTHALMOLOGY AND DENTAL CARE** (November 2005)

- Lasik, OPD and Diagnostics
- Dental 3 chambers
- Support Services and Offices



# SPECIALIST CONSULTS AND HIGH-END DIAGNOSTICS (August 2006)

- GP and Specialist Consults
- Full Diagnostics (including MRI)
- Neurology (EEG and EMG)
- Preventive Health and Chronic Care
- Physiotherapy
- Minor Procedures and Emergencies





## **Second Phase of Expansion**

#### **National Capital Region**

#### Max Balaji Hospital – Patparganj Tertiary Care

- Around 270 inpatient beds with 6 OTs and 1 Cathlab – Launch expected by August 2009
- Tower specialties to include:
  - Oncology
  - IVF
  - Orthopaedics and Joint Replacement
  - Neurosciences
  - Cardiac Care
  - Critical Care

## Max Hospital – Saket South Block Tertiary Care

- Around 85 inpatient beds with 2 OTs –
   Launch expected by September 2009
- Tower specialty Oncology

#### Max Hospital – Shalimar Bagh Tertiary Care / Multi-Speciality

- Potential Bed Capacity around 300 Beds
- Expected launch by 2011
- Funding to be tied-up

#### **Outside National Capital Region**

## Max Hospital – Dehradun High-end Secondary Care

- Around 100 inpatient beds Launch expected by June 2009
- Emergency and Trauma care
- Non-invasive Cardiology
- Joint Replacement and Orthopaedics
- Minimally Invasive Surgeries
- All support Specialities


Land already in place for the Second Phase of expansion

12 Facilities in and around Delhi expected by 2011 with a capacity of around 1500 beds





# Max Healthcare Project Cost and Funding



US\$ 105 million

36

Unfunded – \$15 Mn





- Deliver service focused, world-class healthcare by creating institutions committed to the highest standards of medical and service excellence
- Enhance Service Offerings Organ Transplant, Oncology, Cord Blood Banking, Stem
   Cell Research...
- Grow with a Flexible Expansion Program Own and Build; Management Contracts;
   Brown Field expansions and Public Private Partnerships
- Explore Retail Pharmacy and Diagnostics opportunity
- Human Capital Development through Medical and Nursing Colleges, Technical Training Institutes and tie-up with International Academic and Research Institutes
- Improve Capacity Utilization and Outpatient Volumes



# **Max Speciality Products**




## **Global BOPP Industry**

**BOPP - Global Demand Supply** 



#### **Global Per Capita Consumption of BOPP Film**



## **Key Drivers**


- Global flexible packaging industry market size US\$ 50 billion, of which BOPP Films contribute 70%
- Growth of flexible packaging Industry, nearly 15%
- Competitive advantage of BOPP films over other plastics and traditional products
- Shift from PET to BOPP. (In India BOPP:PET products ratio is nearly 1:2 while globally it is nearly 3:1)
- BOPP films in strong demand from consumer goods industries
- Organised retail and changing urban life styles to further expand demand for BOPP films
- Competitive cost advantage for export markets

39

Source: AMI & Access



## **Business Evolution... into Value Added Products**



Max Speciality Products is much more than packaging...

**Our Focus** 

\*To launch



# **Existing Infrastructure / Operations**

Plant location : Near Chandigarh (250km North of Delhi)

Land : 26 Acres (Additional land being acquired)

Offices : Chandigarh, Delhi, Mumbai, Kolkata, Hyderabad,

Chennai

Plant Capacity : 29,000 TPA – 3 BOPP Film Lines, 3 Metallizers,

**5 Coating Lines** 

Business Quantum : (a) Domestic – 80%

(b) Exports – 20%

Employee Strength : 380 (Average Age – 39 years)

Quality Certification : (a) ISO 9000

(b) ISO 14001 – 2004 (Environment Management System)

(c)OHSAS 18001 - 1999 (Occupational Health Safety Standards)



# Max Speciality Products

### **Differentiators**

- Manufacturer/Supplier of Niche (high margin) and High Barrier Speciality polymer films
- Pioneer in introduction of value added products / technology in India
- International market reach with demonstrated export track record
- Long term relationship with Blue chip customers















- Tripled capacity to 29,000 TPA Achieved over 100% utilization within a year
- Good Human Resource Management unique record of no union
- High skilled team with good operational controls
- Cost & Project management skills
- Strong world class quality systems


- Continually expand market share by capacity enhancements ahead of competition
- Explore new markets outside India by leveraging high-quality products manufactured at lower cost in India



# Max Speciality Products – Key Highlights

# Track Record of Strong Performance...

#### Revenue & Profitability Trend (US\$ Mn)



Key Business Drivers	Unit	Quarter Ended		Q-o-Q	Year Ended		Y-o-Y
		Mar-08	Mar-07	Growth	Mar-08	Mar-07	Growth
a) Sales Quantity - BOPP	Tons	7,180	3,308	117%	23,929	11,985	100%
b) Revenue	US\$ Mn	22.9	11.7	96%	76.5	41.5	84%
c) Profitability:							
<b>Contribution Margin</b>	US\$ Mn	9.3	4.4	111%	30.0	15.5	94%
	%	40.6%	37.6%		39.2%	37.3%	
EBITDA	US\$ Mn	4.2	1.6	163%	12.4	5.3	134%
	%	18.3%	13.7%		16.2%	12.8%	
PBT	US\$ Mn	2.5	0.9	178%	6.1	3.0	103%
	%	10.9%	7.7%		8.0%	7.2%	





# **Max Neeman Medical International**






# **Indian Clinical Research Industry**

#### **Revenue Mix - Clinical Trials**

**Indian Clinical Trials Industry - US\$ 220 Million** 



Industry Projected to grow to US\$ 1.3 Billion by 2012...

#### Need availability gap in years to come

	2001	2005	2010 (Projected)	
No. of trials	142	600	6,000	
Investigators	46	250-300	4,000-5,000	
Trained manpower	200	3,000	50,000	
Study Sites	Metros only	A class cities, few B class towns	All A class towns, many B and C class towns	

## **Key Drivers**

- Huge Patient Population base with Therapeutic Diversity
- Cost Arbitrage
- Huge Talent Pool
- Data Processing Infrastructure for Bio-Informatics
- Favorable Patent Regulations to catalyze exponential growth and improving





# Max Neeman Medical International Contract Research Organization (CRO)

#### **Business Overview**

- Service offerings include...
  - Project Management
  - Site Management
  - Data Management, includes Bio-Statistics and Report Writing
  - Monitoring Services
  - Clinical Trial Material Supply Chain Management Services
- Turns profitable backed by strong order flows
  - Revenue grows three-fold to US\$ 3 Mn
- Confirmed order book of US\$ 8 Mn and BD pipeline of US\$ 20 million
- Strengthening of Business Development efforts...
  - Presence on the East and West Coast in US
  - Strategic alliances for outsourcing clinical trials with mid-sized CROs in US, Italy and Russia
  - Strategic alliances for outsourcing BD efforts in US
- Database of 750 GCP/ICH Principal Investigators

- Position India as a destination for clinical trials
- Target medium and small-sized biotech and pharma companies for clinical trials
- Identify mid-sized CROs for exclusive strategic alliances in US and Europe





## Neeman - Select List of Clients
























































# **Max HealthStaff International**

www.maxhealthstaff.com






### Max HealthStaff International

Max HealthStaff International Limited is a training and healthcare staffing company, founded on world-class quality and service excellence offering trained Indian professionals to healthcare institutions in India and abroad

# Big Gap in Demand/Supply of Healthcare Resources Globally, especially US...projected to increase further



- Current Shortage of Nurses: 200,000
- Increasing every year Expected to be over 400,000 by 2008 and 850,000 by 2020
- Shortage of allied healthcare staffing resources such as occupational and physical therapists, pharmacists, radiographers etc. estimated to be more than 360,000 by 2008
- Shortage of healthcare professionals extends to other geographies such as Singapore, Ireland, Canada, Middle East, Australia etc.





## Max HealthStaff International

#### **Business Overview**

- Annuity based revenue model with cash inflows expected for periods upto 36 months for each placed candidate
- 7 Sourcing and Training centers across Delhi, Chandigarh, Kerala and Chennai
- Alliance with leading healthcare staffing companies in US
- 60 Nurses placed in US working with various hospitals such as Stony Brook, Parkway, Tenet Health, North Shore, Maricopa
- Over 500 nurses in different stages of pipeline 240 nurses in various immigration stages

- Exploring geographies beyond US such as Middle East, Canada, Denmark and Australia for training and placement of nurses
- Expand beyond nurses to other allied healthcare staffing resources
- Develop long-term annuity based arrangements with multiple established healthcare staffing companies
- Focus on healthcare resources with prior experience in critical care segment
- Develop a new vertical for placement of healthcare resources in India and Internationally
- Capitalize on domain expertise in English / IELTS training make it available to other professionals and corporates



## **Disclaimer**

This presentation has been prepared by Max India Limited (the "Company"). No representation or warranty, express or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information presented or contained in the presentation. The past performance is not indicative of future results. Neither the Company nor any of its affiliates, advisers or representatives accepts liability whatsoever for any loss howsoever arising from any information presented or contained in the presentation. The information presented or contained in these materials is subject to change without notice and its accuracy is not guaranteed.

This presentation does not constitute a prospectus or offering memorandum or an offer to acquire any securities and is not intended to provide the basis for evaluation of the securities. Neither this presentation nor any other documentation or information (or any part thereof) delivered or supplied under or in relation to the securities shall be deemed to constitute an offer of or an invitation.

No person is authorised to give any information or to make any representation not contained in and not consistent with this presentation and, if given or made, such information or representation must not be relied upon as having been authorised by or on behalf of the Company any of its affiliates, advisers or representatives.

The Company's Securities have not been and are not intended to be registered under the United States Securities Act of 1993, as amended (the "Securities Act"), or any State Securities Law and unless so registered may not be offered or sold within the United States or to, or for the benefit of, U.S. Persons (as defined in Regulations S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and the applicable State Securities Laws.

This presentation is highly confidential, and is solely for your information and may not be copied, reproduced or distributed to any other person in any manner. Unauthorized copying, reproduction, or distribution of any of the presentation into the U.S. or to any "U.S. persons" (as defined in Regulation S under the Securities Act) or other third parties (including journalists) could prejudice, any potential future offering of shares by the Company. You agree to keep the contents of this presentation and these materials confidential.



#### MAX INDIA LTD.

Max House, Okhla, New Delhi – 110 020

Phone: +91 11 26933601-10 Fax: +91 11 26933619

Website: www.maxindia.com

May 2008 52